Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Innovent Biologics
Biotech
ESMO: Innovent links cytokine to colorectal cancer responses
A phase 1 that combined the candidate with bevacizumab reported a 21.9% response rate, including efficacy in patients with prior immunotherapy use.
Nick Paul Taylor
Sep 18, 2024 9:53am
Innovent links IL-2 fusion protein to responses in small study
Jun 14, 2024 10:00am
Innovent's Tepezza rival closer to China nod after phase 3 win
Feb 20, 2024 8:38am
Next-gen Lilly obesity drug secures first phase 3 win for Innovent
Jan 9, 2024 5:29am
Innovent’s rival to AbbVie, J&J psoriasis drugs clears phase 2
Aug 10, 2022 6:50am
Sanofi pens 'pioneering' cancer drug deal with China's Innovent
Aug 4, 2022 3:07pm